Transcutaneous Bilirubin Nomogram for Predicting Significant Neonatal Hyperbilirubinemia at Discharge Time in Healthy Term and Near-Term Iranian Infants

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Pediatrics, School of Medicine AND Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 Pediatrician, Isfahan, Iran

3 Assistant Professor, Department of Pediatrics, School of Medicine AND Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 َAssociate Professor, Department of Pediatrics, School of Medicine AND Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Hyperbilirubinemia is one of the most common causes of neonatal re-hospitalization; using transcutaneous bilirubin (TCB) measurement nomogram, the aim of this study was to determine the risk of severe hyperbilirobinemia in term and near-term Iranian neonates at discharge time.Methods: 450 healthy newborn infants, with the gestational age of ≥ 35 weeks, weight of ≥ 2 kg, and the age of 12 to 140 hours were enrolled in this randomized-descriptive practical study. Before being discharged, the infant’s bilirubin was measured using Bilichek that was placed on their chest and between two nipples. After being discharged, the newborn infants were followed up. According to the discharge time transcutaneous bilirubin level, the infant's age (in terms of hour), and based on bilirubin nomogram, the newborns were divided into four groups of low-risk, low-medium-risk, high-medium-risk, and high-risk. In following up the infants, if they were suffering hyperbilirobinemia, the bilirubin was measured again.Findings: According to discharge time transcutaneous bilirubin level and the infant's based-on-hour age, 20% of the subjects were included in the low-risk group, 33.1% in low-medium-risk group, 32.2% in high-medium-risk group, and 14.7% in high-risk group. The risk of severe hyperbilirobinemia in followed-up newborns was 1.4%, 6.9%, 13.6%, and 32.8%, in groups 1 to 4, respectively. During this time, 11.9% of the newborns were found to have sever hyperbilirubinemia (more than 95th percentile.Conclusion: By providing bilirubin nomogram, based on transcutaneous bilirubin level and the infant's age (in terms of hour), the severity of future hyperbilirobinemia can be estimated in Iranian healthy newborns. The transcutaneous bilirubin method with bilichek, that is a non-invasive method, can be recommended for all newborns at discharge time.

Keywords

References

  1. Maisels MJ, Kring E. Length of stay, jaundice, and hospital readmission. Pediatrics 1998; 101(6): 995-8.
  2. Friedman MA, Spitzer AR. Discharge criteria for the term newborn. Pediatr Clin North Am 2004; 51(3): 599-618, viii.
  3. American Academy of Pediatrics. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114(1): 297-316.
  4. Varvarigou A, Fouzas S, Skylogianni E, Mantagou L, Bougioukou D, Mantagos S. Transcutaneous bilirubin nomogram for prediction of significant neonatal hyperbilirubinemia. Pediatrics 2009; 124(4): 1052-9.
  5. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999; 103(1): 6-14.
  6. Gourley G, Bhutani V, Johnson L, Kreamer B, Kosorok M, Dalin C. Measurement of serum bilirubin in newborn infants: common clinical laboratory methods versus high performance liquid chromatography (HPLC). Pediatr Res 1998; 43(S4): 260.
  7. Bhutani VK, Gourley GR, Adler S, Kreamer B, Dalin C, Johnson LH. Noninvasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess the risk of severe hyperbilirubinemia. Pediatrics 2000; 106(2): E17.
  8. Tayaba R, Gribetz D, Gribetz I, Holzman IR. Noninvasive estimation of serum bilirubin. Pediatrics 1998; 102(3): E28.
  9. Ebbesen F, Rasmussen LM, Wimberley PD. A new transcutaneous bilirubinometer, BiliCheck, used in the neonatal intensive care unit and the maternity ward. Acta Paediatr 2002; 91(2): 203-11.
  10. Rubaltelli FF, Gourley GR, Loskamp N, Modi N, Roth-Kleiner M, Sender A, et al. Transcutaneous bilirubin measurement: a multicenter evaluation of a new device. Pediatrics 2001; 107(6): 1264-71.
  11. Poland RL, Hartenberger C, McHenry H, Hsi A. Comparison of skin sites for estimating serum total bilirubin in in-patients and out-patients: chest is superior to brow. J Perinatol 2004; 24(9): 541-3.
  12. Sarici SU, Serdar MA, Korkmaz A, Erdem G, Oran O, Tekinalp G, et al. Incidence, course, and prediction of hyperbilirubinemia in near-term and term newborns. Pediatrics 2004; 113(4): 775-80.
  13. Imani M, Mohammadi M. Comparison of change pattern of serum and transcutaneousbilirubin in hyper bilirubinemic neonates. Tabib-e-Shargh 2004; 6(3): 193-7. [In Persian].
  14. Ghaffari V, Vahidshahi K. Study on diagnostic value of transcutaneous bilirubinometry in neonate patients. J Mazandaran Univ Med Sci 2003; 13(40): 43-50. . [In Persian].
  15. Rostami N, Shahverdizadeh MA. Determining the diagnostic power of transcutaneous bilirubinometry (TCB). Pajouhesh Dar Pezeshki 2007; 31(4): 351-3. [In Persian].
Journal of Isfahan Medical School
Volume 31, Issue 270 - Serial Number 270
November and December 2014
Pages 2373-2381

Files

History

  • Receive Date: 11 August 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics